MedTrace Logo

Fluciclovine (18F) Imaging of Breast Cancer

NCT03036943 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-12-19

No results posted yet for this study

Summary

The purpose of this study is to find out what a new amino acid-based PET agent, fluciclovine (18F), can tell us about breast cancer biology (how it grows and develops), and quantify the differences in fluciclovine (18F) uptake between breast cancer subtypes. This will inform further work to investigate its use in breast cancer management.

Conditions

Interventions

RADIATION

Fluciclovine

Fluciclovine (18F) PET/CT scan completed \>= 48 hours prior to surgical resection for breast cancer

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Adrian Harris, Prof · University of Oxford

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2018-12-04
Completion
2018-12-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03036943 on ClinicalTrials.gov